1,091 results
Page 15 of 55
6-K
EX-99.1
tw6sz
4 Mar 13
Live Filing
12:00am
6-K
EX-99.1
mhsfyzz14etm015
22 Feb 13
Additional QNASL® (beclomethasone dipropionate) Nasal Aerosol Data to be Presented at Annual Allergy Meeting
12:00am
6-K
EX-99.1
q2r1n77
14 Feb 13
Live Filing
12:00am
6-K
EX-99.1
9562v5stz99otg
11 Feb 13
Teva Pharmaceuticals Announces Appointment of Dr. Arie Belldegrun to Board of Directors
12:00am
6-K
EX-99.1
wyiq3u on0
7 Feb 13
Teva Reports Fourth Quarter and Full Year 2012 Results
12:00am
6-K
EX-99.1
0vf 3wn8id91k4fxj
5 Feb 13
Teva Announces First Patient Enrolled In Largest Clinical Study to Date Evaluating Azilect® for Mild Cognitive Impairment In Parkinson’s Disease
12:00am
6-K
EX-99.1
ar23tago20 1wzu5x70j
31 Jan 13
Teva Announces Termination of Agreements with Curetech
12:00am
6-K
EX-99.1
qrdjm 9kc7p
23 Jan 13
Live Filing
12:00am
6-K
EX-2.1
nzqdd8trnqzp eq1
20 Dec 12
Current report (foreign)
12:00am
6-K
EX-5.3
3pep6i4 af3u0626avy2
18 Dec 12
Current report (foreign)
12:00am
6-K
EX-99.1
bm22h4bh98w jzo12j
18 Dec 12
Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility
12:00am
6-K
EX-99.1
43g72ccpl97u0kjgdbkl
18 Dec 12
Live Filing
12:00am
6-K
EX-1.1
2jl 4dnrpnn
18 Dec 12
Current report (foreign)
12:00am
6-K
EX-99.1
uidepr10ppzgvn93
17 Dec 12
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market
12:00am
424B5
tck dgk11q884j
14 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
zk8 3t3nef1
14 Dec 12
Teva Announces Pricing of $2.0 Billion of Senior Notes
12:00am
424B5
8821g7sutigoowzai2wu
13 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
jb9cqbn5 ro
13 Dec 12
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook
12:00am
6-K
EX-99
osgeysb
11 Dec 12
Live Filing
12:00am